Ventricular septal defects account for up to 40% of all congenital cardiac malformations. The
diagnosis encompasses a broad range of anomalies, including isolated defects and those …

Background—Our purpose was to describe a 13-year experience with patients undergoing
transcatheter device closure of unrepaired congenital or postoperative residual ventricular …

Aim To report the experience of 23 tertiary referral European Centres on transcatheter
closure of congenital ventricular septal defects (VSD). Methods and results Implantation of …

Objectives: This phase I study attempted to report the initial safety and efficacy results of
transcatheter closure of perimembranous ventricular septal defects (PmVSDs) using the new …

目的探讨膜周部室间隔缺损(ventricular septal defect, VSD) 经导管介入治疗的并发症及其预防.
方法2002 年7 月r 2004 年5 月, 262 (男138, 女124) 例膜周部VSD 患儿, 年龄2= 18 (9. 3±5. 8) …

Objective: To report the immediate and midterm results of transcatheter closure of
perimembranous ventricular septal defect (PmVSD) using the Amplatzer membranous VSD …

Transcatheter closure of congenital ventricular septal defect (VSD) using various devices is
gaining acceptance in selected cases of perimembranous and muscular defects, avoiding …

Transcatheter closure of perimembranous ventricular septal defects with coils or devices
designed to close other lesions may be complicated by embolization or aortic insufficiency …

OBJECTIVE: The development of the Amplatzer Membranous VSD Occluder (AGA Medical
Corp, Plymouth, Minn) for closure of the perimembranous ventricular septal defect has …

Surgical closure of multiple muscular ventricular septal defects (MVSDs) is associated with
mortality and morbidity; therefore, both surgeons and cardiologists welcome a nonsurgical …